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Abstract
This study was aimed at investigating the effects of
lamotrigine (LTG) on electrically evoked field excitatory
postsynaptic potentials (fEPSP) and population spikes in
the CA1 hippocampal region of guinea pigs. The concen-
tration response curves showed different actions of LTG
on fEPSP and on population spikes. The data are in con-
trast to previous findings that suggest the drug acts pri-
marily on presynaptic sites via a blockade of the release
of excitatory amino acids. In the range of therapeutic
plasma levels, synaptic transmission was not affected.
Copyright © 2000 S. Karger AG, Basel
Introduction
The new antiepileptic drug lamotrigine (LTG) has
been used in the treatment of focal epilepsy with or with-
out secondary generalization [1, 2]. Additionally, there
are now several reports indicating efficacy in the treat-
ment of bipolar affective disorders [3, 4]. LTG is believed
to block presynaptic voltage-sensitive sodium channels,
which results in an inhibition of the release of excitatory
amino acids [5, 6]. Furthermore, antagonistic effects of
LTG on calcium channels have been found in rat cortical
neurons and in the CA1/CA3 hippocampal area of guinea
pigs [7, 8].
Methods
Hippocampal slices were prepared as described previously. For
preparation of concentration response curves, LTG was applied for
30 min, and the maximum change was measured. Each concentra-
tion was used on one slice only. The CA1 region of the hippocampus
was identified by transmission microscopy and glass microelectrodes
filled with 3 M NaCl were used to detect population spikes and
fEPSP in the pyramidal cell layer or in the dendritic region of CA1,
respectively. Test stimuli were generated by isolated pulse stimula-
tors. Field potential changes (fEPSP and population spikes) were
evoked by constant stimulation (f  = 0.066 Hz, duration 50 Ìs, I =
0.8–4 mA) with an insulated bipolar tungsten electrode, placed in the
stratum radiatum of CA1. The intensity of test stimulation was
adjusted to evoke two thirds of maximal fEPSP or population spikes,
respectively.
Results
The concentration response curves showed different
actions of LTG in concentrations near therapeutic plasma
levels (10 ÌM) on fEPSP and population spikes. The ini-
tial slopes of fEPSP were not affected, whereas the ampli-
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tudes of population spikes were significantly decreased by
15.1 B 4.2%. Higher concentrations of LTG decreased
both fEPSP slopes and population spikes amplitudes;
however, effects on population spikes were much stron-
ger. Those effects were reversible after a 30-min wash-out
period.
Discussion
The release of excitatory amino acids from presynaptic
sites of the synaptic cleft as well as antagonistic actions on
the various glutamate receptors are possible targets for
drugs modulating synaptic transmission and excitability
in the CA1 region of the hippocampus. LTG is believed to
block voltage-sensitive sodium channels with a resulting
decrease in glutamate release [5, 6]. The measurement of
fEPSP may provide some evidence for a suspected modu-
lation of synaptic transmission by LTG. Our experiments
do not show any change in the slope of fEPSP at concen-
trations up to 10 ÌM LTG. Therefore, no significant
influence on the neurotransmitter release can be pre-
sumed in this concentration range. However, 10 ÌM LTG
is a concentration that clearly affects amplitudes of popu-
lation spikes. A concentration of 10 ÌM LTG in our
experimental setting corresponds to estimated therapeut-
ic plasma levels of about 4–16 ÌM in humans, especially if
55% plasma protein binding is taken into account [9]. We
have found effects of LTG on neurotransmitter release
only for concentrations far above the pharmacologically
relevant ones. However, at these concentrations, effects of
LTG on population spikes were much stronger than on
fEPSP. This is in contradiction to previous reports and
may be due to higher concentrations or a pharmacologi-
cally induced transmitter release in those studies [5, 10,
11].
Measurements of population spikes are important in
understanding the effects of LTG on the integration of
synaptic signals into a neuronal output. Possible mecha-
nisms for the decrease of population spike amplitudes
reported here are well-known inhibitions of voltage-
dependent sodium channels [12–14] and antagonistic ef-
fects of LTG on calcium channels [7, 8] or modulation of
transient potassium outward currents as recently reported
[15]. This might explain a reduced neuronal excitability
and antiepileptic effects of LTG.
In conclusion, our experiments reveal different effects
of LTG on synaptic transmission and on postsynaptic
neuronal sites, whereas in the range of therapeutic plasma
levels, synaptic transmission was unaffected.
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